These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 9120416)

  • 21. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).
    Durelli L; Verdun E; Barbero P; Bergui M; Versino E; Ghezzi A; Montanari E; Zaffaroni M;
    Lancet; 2002 Apr; 359(9316):1453-60. PubMed ID: 11988242
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of interferon beta 1b for multiple sclerosis. Importance of relapses must not be underestimated.
    Cardy P
    BMJ; 1996 Nov; 313(7067):1263. PubMed ID: 8939142
    [No Abstract]   [Full Text] [Related]  

  • 23. Disease-modifying drugs for relapsing-remitting multiple sclerosis and future directions for multiple sclerosis therapeutics.
    Rudick RA
    Arch Neurol; 1999 Sep; 56(9):1079-84. PubMed ID: 10488808
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of patients receiving interferon beta-1b for multiple sclerosis: report of a consensus conference.
    Lublin FD; Whitaker JN; Eidelman BH; Miller AE; Arnason BG; Burks JS
    Neurology; 1996 Jan; 46(1):12-8. PubMed ID: 8559358
    [TBL] [Abstract][Full Text] [Related]  

  • 25. What is new in the treatment of multiple sclerosis?
    Weinstock-Guttman B; Jacobs LD
    Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b.
    Antonelli G; Simeoni E; Bagnato F; Pozzilli C; Turriziani O; Tesoro R; Di Marco P; Gasperini C; Fieschi C; Dianzani F
    J Neurol Sci; 1999 Oct; 168(2):131-6. PubMed ID: 10526196
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of interferons in demyelinating disease.
    Johnson KP
    J Neural Transm Suppl; 1997; 49():111-5. PubMed ID: 9266420
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interferon beta treatment for multiple sclerosis: persisting questions.
    Goodkin DE
    Mult Scler; 1996 Jul; 1(6):321-4. PubMed ID: 9345408
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Appropriate design and outcome measures in multiple sclerosis clinical trials.
    Greenstein JI
    Eur J Neurol; 2001 Sep; 8(5):503-6. PubMed ID: 11554918
    [No Abstract]   [Full Text] [Related]  

  • 30. Interferon beta-1b.
    Rudge P
    Lancet; 1994 Nov; 344(8935):1511. PubMed ID: 7968150
    [No Abstract]   [Full Text] [Related]  

  • 31. Betaseron: the new MS treatment.
    Kelley CL; Smeltzer SC
    J Neurosci Nurs; 1994 Feb; 26(1):52-6. PubMed ID: 8195651
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Autoimmune events during interferon beta-1b treatment for multiple sclerosis.
    Durelli L; Ferrero B; Oggero A; Verdun E; Bongioanni MR; Gentile E; Isoardo GL; Ricci A; Rota E; Bergamasco B; Durazzo M; Saracco G; Biava MA; Brossa PC; Giorda L; Pagni R; Aimo G
    J Neurol Sci; 1999 Jan; 162(1):74-83. PubMed ID: 10064173
    [TBL] [Abstract][Full Text] [Related]  

  • 33. T-cell interferon gamma receptor binding in interferon beta-1b-treated patients with multiple sclerosis.
    Bongioanni P; Lombardo F; Moscato G; Mosti S; Meucci G
    Arch Neurol; 1999 Feb; 56(2):217-22. PubMed ID: 10025427
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interferon-beta 1b treatment decreases tumor necrosis factor-alpha and increases interleukin-6 production in multiple sclerosis.
    Brod SA; Marshall GD; Henninger EM; Sriram S; Khan M; Wolinsky JS
    Neurology; 1996 Jun; 46(6):1633-8. PubMed ID: 8649562
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Natural killer cells in relapsing-remitting MS: effect of treatment with interferon beta-1B.
    Kastrukoff LF; Morgan NG; Zecchini D; White R; Petkau AJ; Satoh J; Paty DW
    Neurology; 1999 Jan; 52(2):351-9. PubMed ID: 9932956
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Managing side effects of interferon-beta in patients with relapsing-remitting multiple sclerosis.
    Munschauer FE; Kinkel RP
    Clin Ther; 1997; 19(5):883-93. PubMed ID: 9385477
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Annualized relapse rate of first-line treatments for multiple sclerosis: a meta-analysis, including indirect comparisons versus fingolimod.
    Roskell NS; Zimovetz EA; Rycroft CE; Eckert BJ; Tyas DA
    Curr Med Res Opin; 2012 May; 28(5):767-80. PubMed ID: 22462530
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunomodulatory treatment in multiple sclerosis: experience at a Brazilian center with 390 patients.
    Tilbery CP; Mendes MF; Oliveira BE; Thomaz RB; Kelian GR
    Arq Neuropsiquiatr; 2006 Mar; 64(1):51-4. PubMed ID: 16622553
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of steroids on Gd-enhancing lesions before and during recombinant beta interferon 1a treatment in relapsing remitting multiple sclerosis.
    Gasperini C; Pozzilli C; Bastianello S; Koudriavtseva T; Galgani S; Millefiorini E; Paolillo A; Horsfield MA; Bozzao L; Fieschi C
    Neurology; 1998 Feb; 50(2):403-6. PubMed ID: 9484362
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS.
    Lancet; 1998 Nov; 352(9139):1491-7. PubMed ID: 9820296
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.